Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02311790 · ClinicalTrials.gov registry record · NA

Palmitoleic Isomer Study

A NA study, sponsored by Tufts University.

Completed
Registry status
NA
Development phase
17
Enrollment target

NCT02311790 is a NA study that has completed, run by Tufts University. The registered enrollment target is 17 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02311790, a NA study, has completed, sponsored by Tufts University.

COMPLETED
Registry status
NA
Development phase
17 participants
Enrollment target

Study Summary

Trans-palmitoleic acid (trans-C16:1) is a naturally occurring trans fatty acid present in small quantities in foods, most notably in dairy products. Observational evidence suggests a positive association between trans-C16:1 and insulin sensitivity, and negative association with risk of developing type 2 diabetes mellitus \[1-3\]. Cis-palmitoleic acid (cis-C16:1) is found naturally in foods and is particularly high in macadamia nuts and oil extracted from the sea buckthorn plant. Animal models suggest that this palmitoleic acid isomer also improves insulin sensitivity and reduces metabolic dysfunction. This pilot dosing study is necessary to inform the design of a larger trial to test the hypothesis that both trans-C16:1 and cis-C16:1 improve insulin resistance but at different doses. Plasma phospholipid fatty acid profiles will be used as the primary outcome measure.

Interventions

  • DIETARY_SUPPLEMENT Trans-C16:1 supplement
  • DIETARY_SUPPLEMENT Cis-C16:1 supplement

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2015-07
Est. Completion 2017-04
Phase NA

Sponsor

Tufts University

163 total trials

What the Registry Record Tells You About NCT02311790

The ClinicalTrials.gov registry entry for NCT02311790 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts University, which has 163 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Trans-C16:1 supplement is the first listed.

NCT02311790 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02311790 about?

NCT02311790 is a clinical study titled "Palmitoleic Isomer Study". Trans-palmitoleic acid (trans-C16:1) is a naturally occurring trans fatty acid present in small quantities in foods, most notably in dairy products. Observational evidence suggests a positive association between trans-C16:1 and insulin sensitivity, and negative association with risk of developing ty...

What is the current status of trial NCT02311790?

This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2015-07. Estimated completion is 2017-04.

What interventions are being tested in trial NCT02311790?

The interventions under investigation include: Trans-C16:1 supplement (DIETARY_SUPPLEMENT), Cis-C16:1 supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02311790?

This trial is sponsored by Tufts University, which has 163 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.